Bank of Montreal
AVDL

Bank of Montreal’s Avadel Pharmaceuticals AVDL Stock Holding History

Bank of Montreal’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-39,500
Closed -$286K – 4622
2020
Q1 		$286K Buy
39,500
+39,200
+13,067% +$301K ﹤0.01% 2210
2019
Q4 		$2K Buy
+300
New +$1.58K ﹤0.01% 4769

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Bank of Montreal's AVDL Position: Q2 2020 in Review

Bank of Montreal sold out of Avadel Pharmaceuticals (AVDL) in Q2 2020, closing a stake of 39,500 shares — an estimated $286K sold.

Bank of Montreal first reported a position in AVDL in Q4 2015 and held it in 16 quarters. The position peaked at $286K in Q1 2020. 74 funds tracked by Wall St. Rank hold AVDL as of Q2 2020.

  • Bank of Montreal reported no remaining Avadel Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Bank of Montreal sold 39,500 Avadel Pharmaceuticals shares in Q2 2020, an estimated $286K.
  • Bank of Montreal first reported a position in Avadel Pharmaceuticals in Q4 2015 and held it in 16 quarters.
  • Bank of Montreal's Avadel Pharmaceuticals position peaked at $286K in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2020.

Based on Bank of Montreal's 13F filing for Q2 2020, filed 12 Aug 2020.